# Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy

Study · id `cardio:ct-nct05700097` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05700097](<https://clinicaltrials.gov/study/NCT05700097>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05700097

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT05700097. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-30 (actual); primary completion 2023-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT05700097, source copy `cardio:ctgov-nct05700097-2023-01-26`, retrieved 2026-10-26)
- Started: 2022-09-30 (actual) (ClinicalTrials.gov record NCT05700097, source copy `cardio:ctgov-nct05700097-2023-01-26`, retrieved 2026-10-26)
- Primary completion: 2023-09-30 (anticipated) (ClinicalTrials.gov record NCT05700097, source copy `cardio:ctgov-nct05700097-2023-01-26`, retrieved 2026-10-26)
- Completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05700097, source copy `cardio:ctgov-nct05700097-2023-01-26`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05700097, source copy `cardio:ctgov-nct05700097-2023-01-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05700097-2023-01-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Dengzhanxixin Injection
- Intervention (Drug): Placebo injection
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: 782c41b385fa6be8dad71a1d78668f6bd11843f9f509893326a87aaf32570ff6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
